Empirical Spine Completes Enrollment in Pivotal IDE Clinical Trial Studying LimiFlex in Degenerative Spondylolisthesis

IN.PACT AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT™ AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.

Martell Diagnostic Laboratories Announces HERTEST: Groundbreaking Way to Detect Effectiveness of Breast Cancer RX Globally

HERTEST is a blood test that looks for a protein called human epidermal growth factor receptor (HER2), which is shed into the blood stream of patients with growing breast cancer tumors.

ESPRIT CAM Improves Productivity for Long Part Machining by Automating Multi-spindle Program Creation

ESPRIT CAM: New computer-aided-manufacturing (CAM) technology has been introduced by ESPRIT CAM, part of Hexagon’s Manufacturing Intelligence division that provides manufacturers with the control and flexibility needed to use multi-spindle and multi-channel computer-numerical-control (CNC) machinery for the machining of long parts.

July 17, 2020

Empirical Spine, Inc., maker of the LimiFlex Paraspinous Tension Band, today announced completion of enrollment in its U.S. IDE trial studying the use of LimiFlex with a decompression for patients suffering from degenerative spondylolisthesis with lumbar spinal stenosis.

Empirical Spine notes the trial compares outcomes of patients who receive either LimiFlex or transforaminal lumbar interbody fusion (TLIF) after decompression surgery.  The trial reached its target of 135 LimiFlex patients enrolled into the investigational arm of the trial in December 2019 and the control arm has achieved its target of 160 patients.  To date, a total of 168 study subjects have reached 12 months follow up.  The results of the LimiFlex trial will form the basis for a PMA application to the U.S. Food and Drug Administration (FDA), anticipated by the end of 2021.

“As we reach this major milestone, our thanks go out to the fantastic partners who have joined us in the LimiFlex trial,” said Richard Treadwell, CEO of Empirical Spine. “We recognize and appreciate the hard work and dedication of the surgeon investigators and research coordinators, as well as the enthusiasm of the patients in participating in this investigation of a non-fusion alternative for degenerative spondylolisthesis.  We would also like to thank our review team at FDA for the collaborative process that has allowed us to complete study enrollment with minimal impacts to the PMA submission timing from COVID-19 disruptions.”

Co-primary investigator Rick Sasso, MD, of the Indiana Spine Group commented, “My experience with LimiFlex has been very positive.  The device may offer a minimally invasive way to stabilize the spine yet preserve motion.  Many patients are extremely interested in less invasive stabilization options that avoid the complications of fusion, so they are attracted to LimiFlex.”

William Welch, MD of the University of Pennsylvania and co-principal investigator of the LimiFlex IDE study added “I am encouraged by the clinical outcomes and results we have seen so far in the study.  LimiFlex is an exciting new possibility for patients currently undergoing fusion for degenerative spondylolisthesis and would offer much faster recovery for patients, significant savings for payors and more surgical offerings for spine surgeons.”

Traditional means of stabilizing the spine after decompression surgery involve lengthy, invasive procedures that use bone graft material, combined with instrumentation such as pedicle screws and rods, to fuse two or more vertebrae together.  The resulting constructs reduce spinal flexibility and magnify the forces experienced by adjacent levels, often leading to accelerated degeneration of the adjacent spinal segments.  While the acute clinical outcomes may be excellent, this accelerated degeneration can lead to longer term issues, sometimes requiring additional surgery.

Occasionally, patients with this instability diagnosis forego stabilization in favor of standalone decompression surgery, which carries a high risk of recurrence and reoperation due to progressive instability.

The LimiFlex was developed as a way of bridging this therapy gap by offering a minimally invasive way to stabilize the spine yet preserve motion.  The device aims to restore the spine’s natural biomechanics, along parameters such as stiffness, lordosis, and facet engagement.

The LimiFlex IDE trial is a prospective, multi-center, controlled clinical trial studying the safety and efficacy of the LimiFlex Paraspinous Tension Band compared to TLIF in patients suffering from degenerative spondylolisthesis and lumbar spinal stenosis.  The study endpoint is the rate of overall clinical success at 24 months. The goal is to show that patients can achieve fusion-equivalent results – without the fusion.

The device received the CE mark in 2009 and has been implanted with excellent results in over 2,000 European patients.

spot_img

DON'T MISS

Related Articles